BENZOCLIDINE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C14H17NO2
Molecular Weight	231.2903
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(OC1CN2CCC1CC2)C3=CC=CC=C3

InChI

InChIKey=AHKAOMZZTQULDS-UHFFFAOYSA-N

InChI=1S/C14H17NO2/c16-14(12-4-2-1-3-5-12)17-13-10-15-8-6-11(13)7-9-15/h1-5,11,13H,6-10H2

HIDE SMILES / InChI

Molecular Formula	C14H17NO2
Molecular Weight	231.2903
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://drdoping.com/instructions/Oxylidin-solution-for-injections/ | http://www.medicus.ru/handbook/drugs/benzoklidin.phtml | https://www.ncbi.nlm.nih.gov/pubmed/4384680

Benzoclidine (Oxylidin) exerts tranquilizing and hypotensive actions. It reduces the excitability of the central nervous system, enhances the effect of hypnotic drugs, analgesics and local anesthetics, has a moderate antihypertensive effect, reduces the excitability of the vasomotor centers, has anti-arrhythmic activity. Benzoclidine is marke indicated for the treatment of anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
neurological system process 6 Target ID: GO:0050877 Sources: http://drdoping.com/instructions/Oxylidin-solution-for-injections/	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Anxiety 275 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4384745 https://www.ncbi.nlm.nih.gov/pubmed/4384680	Primary	Approved 8583	Benzoclidine Approved Use Anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.
Depression 240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4384745 https://www.ncbi.nlm.nih.gov/pubmed/4384680	Primary	Approved 8583	Benzoclidine Approved Use Anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.
Hypertension 575 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4384680	Primary	Approved 8583	Benzoclidine Approved Use Anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.

PubMed

Title	Date	PubMed
[Effectiveness of health resort climatic treatment including oxylidin electrophoresis and the correction of the climatic adaptation of patients with the sequelae of viral encephalitis].	1988-07-01	2973684
[Effect of hypotensive preparations on hemodynamics in persons of different sexes and ages].	1982-11-01	7152000
[Effect of antihypertensive agents on indices of systemic hemodynamics and baroreceptors reflexes in man].	1981-01-01	7262303
[Effect of antihypertensive compounds on the hypothalamic regulation of baroreceptor reflexes].	1980-01-01	7379990
[Antiarrhythmic action of oxylidin].	1973-04	4711308
[Chromatographic analysis of aceclidine and oxylidin solutions for injections].	1971-01-01	4396295
[The use of oxylidin in psychiatric practice].	1968	4384745
[Oxylidin--a new preparation of tranquilizing and hypotensive action].	1966-02	4384680
[Experience in the treatment of hypertensive patients with oxylidin under polyclinical conditions].	1965-11	4381134
[CLINICAL TESTING OF OXYLIDIN, A NEW HYPOTENSIVE AGENT, IN THE TREATMENT OF HYPERTENSION].	1965-02	14270384
[OXYLIDIN THERAPY OF PATIENTS WITH CEREBROVASCULAR DISEASES WITH MENTAL DISORDERS].	1965	14335737
[ON THE RELATIONSHIP BETWEEN THE HYPOTENSIVE EFFECT OF OXYLIDIN AND ITS EFFECT ON CENTERS OF THE MEDULLA OBLONGATA AND CARDIAC ACTIVITY].	1964-01-01	14187183

Sample Use Guides

In Vivo Use Guide

Average therapeutic dose oral, subcutaneous and intramuscular injection 0.02 - 0.3 grams daily, the duration of treatment 3-8 weeks.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:15:55 GMT 2025` Edited by `admin` on `Mon Mar 31 18:15:55 GMT 2025`
Record UNII	G84189YY06
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BENZOCLIDINE

Official Name

English

3-QUINUCLIDINOL DL-FORM BENZOATE (ESTER) [MI]

Preferred Name

English

3-QUINUCLIDINOL BENZOATE (ESTER)

Common Name

English

NSC-760346

Code

English

benzoclidine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29756